Phospholipase

Phospholipase is a member of a very complex group of enzymes that break down phospholipids into fatty acids and other compounds. Phospholipases are defined by the enzymatic reaction they catalyze. The classes are phospholipase A, which has members A1 and A2; phospholipase B, which can carry out the reactions of both A1 and A2; phospholipase C; and phospholipase D.

Phospholipase A_2 (PLA_2) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Phospholipase C (PLC) converts phosphatidylinositol 4,5-bisphosphate (PIP_2) to inositol 1,4,5-trisphosphate (IP_3) and diacylglycerol (DAG). DAG and IP_3 each control diverse cellular processes and are also substrates for synthesis of other important signaling molecules. PLC is thus central to many important interlocking regulatory networks. Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival.

(R)-Bromoenol lactone

((R,E)-Bromoenol lactone) Cat. No.: HY-117068

(R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of **calcium-independent phospholipaseγ(iPLA2γ)(/b). (R)-BEL inhibits human recombinant iPLA2γ with an IC_{50} of approximately 0.6 μM.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Bromoenol lactone

((S)-BEL; (S,E)-Bromoenol lactone) Cat. No.: HY-120986

(S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of **calcium-independent phospholipase A_2β (iPLA$_2$β)** that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC_{50} of 2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Linoleoyl Glycerol

(1-Linoleoyl-rac-glycerol; 1-Monolinolein) Cat. No.: HY-111346

1-Linoleoyl Glycerol is a fatty acid glycerol.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

1-Naphthaleneacetic acid

(1-Naphthylacetic acid) Cat. No.: HY-18570

1-Naphthaleneacetic acid (1-Naphthylacetic acid), a synthetic auxin, can promote plant growth. 1-Naphthaleneacetic acid is also an inhibitor of **PLA_2**, with an IC_{50} of 13.16 μM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

1-Naphthaleneacetic acid potassium salt

(Potassium 1-Naphthaleneacetate) Cat. No.: HY-18570A

1-Naphthaleneacetic acid potassium salt (Potassium 1-Naphthaleneacetate), a synthetic auxin, can promote plant growth. 1-Naphthaleneacetic acid potassium salt is also an inhibitor of **PLA_2**, with an IC_{50} of 13.16 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide

Cat. No.: HY-100287

2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Nitrocoumarin

Cat. No.: HY-111919

3-Nitrocoumarin (3-NC) is a potent and selective **Phospholipase C-γ (PLC-γ)** inhibitor.



Purity: 100.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

7-Hydroxycoumarinyl arachidonate

(7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate) Cat. No.: HY-116141

7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

AA26-9

Cat. No.: HY-18522

AA26-9 is a potent and broad spectrum **serine hydrolase** inhibitor. AA26-9 targets included serine peptidases, lipases, amidases, esterases, and thioesterases. AA26-9 shows inhibitory activity against approximately 1/3 of the 40+ serine hydrolases detected in immortalized T cell lines .



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AACOCF3

(Arachidonyl trifluoromethyl ketone) Cat. No.: HY-108611

AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa **cytosolic phospholipase A2 (cPLA2)**.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Alminoprofen

(EB-382) Cat. No.: HY-17485

Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both **secretory phospholipase A_2 ($sPLA_2$)** and **COX-2**.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Alminoprofen-d3

(EB-382-d3) Cat. No.: HY-17485S

Alminoprofen-d3 (EB-382-d3) is the deuterium labeled Alminoprofen. Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aristolochic acid C

Cat. No.: HY-N1450

Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A_2 (**PLA2**) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARN19874

Cat. No.: HY-118994

ARN19874 is a selective, reversible uncompetitive N-acylphosphatidylethanolamine phospholipase D **(NAPE-PLD)** activity inhibitor with an **IC_{50}** of ~34 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atg4B-IN-2

Cat. No.: HY-144636

Atg4B-IN-2 is a potent competitive **Atg4B** inhibitor with **K_i** value of 3.1 μM, also possesses declining **PLA_2** inhibitory potency, **IC_{50}**s of 11 μM and 3.5 μM for Atg4B and PLA_2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromoenol lactone

((6E)-Bromoenol lactone) Cat. No.: HY-107411

Bromoenol lactone ((6E)-Bromoenol lactone) is a suicide-based irreversible, selective, potent inhibitor of **calcium-independent phospholipase A_2 ($iPLA_2\beta$)** with an **IC_{50}** value of approximately 7 μM, which inhibits antigen-stimulated mast cell exocytosis without blocking Ca^{2+} influx.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Bromoenol lactone-d7

((6E)-Bromoenol lactone-d7) Cat. No.: HY-107411S

Bromoenol lactone-d7 ((6E)-Bromoenol lactone-d7) is the deuterium labeled Bromoenol lactone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cambinol

Cat. No.: HY-100732

Cambinol is a **SIRT1** and **SIRT2** inhibitor with **IC_{50}** values of 56 μM and 59 μM, respectively. Cambinol is a potent brain penetrant **neutral sphingomyelinase (N-SMase)** inhibitor (exosome inhibitor).



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CAY10502

Cat. No.: HY-116301

CAY10502 is a potent, calcium-dependent **cytosolic phospholipase A2 α** ($cPLA_2\alpha$) inhibitor with an **IC_{50}** of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10594

Cat. No.: HY-121983

CAY10594 is a potent **phospholipase D2 (PLD2)** inhibitor both in vitro (**IC_{50}**=140 nM) and in cells (**IC_{50}**=110 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10650

Cat. No.: HY-10801

CAY10650 is a highly potent cytosolic phospholipase A2α **(cPLA2α)** inhibitor with an **IC_{50}** value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

CCT129957

Cat. No.: HY-111208

CCT129957 is an indole derivative and a potent **phospholipase C-γ (PLC-γ)** inhibitor with an **IC_{50}** of ~3 μM and a **GC_{50}** of 15 μM. CCT129957 inhibits Ca^{2+} release in squamous carcinoma cells at ~15 μM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Compound 48/80 trihydrochloride

(C48/80 trihydrochloride)

Cat. No.: HY-130592

Compound 48/80 trihydrochloride (C48/80 trihydrochloride) is a mixture of condensation products of N-methyl-p-methoxyphenethylamine with formaldehyde. Compound 48/80 trihydrochloride is also a **histamine** releaser and a **mast cell** degranulator.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

D-Erythro-dihydrosphingosine

Cat. No.: HY-W019838

D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A_2α (**$cPLA_2$α**) activity.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

D-Erythro-dihydrosphingosine-d7

Cat. No.: HY-W019838S

D-Erythro-dihydrosphingosine-d7 is the deuterium labeled D-Erythro-dihydrosphingosine. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A_2α (**$cPLA_2$α**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D609

Cat. No.: HY-70072

D609 is a selective competitive inhibitor of **phosphatidyl choline-specific phospholipase C (PC-PLC)**, with **K_i** of 6.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Darapladib

(SB-480848)

Cat. No.: HY-10521

Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA_2**) with **IC_{50}** of 0.25 nM.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

DPTIP

Cat. No.: HY-131002

DPTIP is a potent brain penetrant **neutral sphingomyelinase 2 (N-SMase 2)** inhibitor (exosome inhibitor), with an **IC_{50}** of 30 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ecopladib

(PLA 725)

Cat. No.: HY-U00037

Ecopladib is a sub-micromolar inhibitor of cytosolic **phospholipase A2α (cPLA2α)**, with **IC_{50}**s of 0.15 μM and 0.11 μM in the GLU micelle and rat whole blood assays, respectively.



Purity: 95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

FIPI

(5-Fluoro-2-indolyl deschlorohalopemide)

Cat. No.: HY-12807

FIPI is a derivative of halopemide which potently inhibits both **PLD1** and **PLD2** with **IC_{50}**s of 25 nM and 20 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2647544

Cat. No.: HY-145653

GSK2647544 is an orally available, selective inhibitor of **Lp-PLA2**. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

GW4869

Cat. No.: HY-19363

GW4869 is a noncompetitive **neutral sphingomyelinase (N-SMase)** inhibitor with an IC_{50} of 1 μM. GW4869 is an inhibitor of **exosome** biogenesis/release.



Purity: 95.57%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Halopemide

Cat. No.: HY-119093

Halopemide is a potent **phospholipase D (PLD)** inhibitor, with IC_{50}s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a **dopamine receptors** antagonist, and acts a psychotropic agent.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Lansoprazole

(AG-1749)

Cat. No.: HY-13662

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant **neutral sphingomyelinase (N-SMase)** inhibitor (exosome inhibitor).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

LCL521

Cat. No.: HY-103593

LCL521 is an **acid ceramidase** (**ACDase**) inhibitor. LCL521 also inhibits the lysosomal **acid sphingomyelinase** (**ASMase**).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LCL521 dihydrochloride

Cat. No.: HY-103593A

LCL521 dihydrochloride is an **acid ceramidase** (**ACDase**) inhibitor. LCL521 also inhibits the lysosomal **acid sphingomyelinase** (**ASMase**).



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LEI-401

Cat. No.: HY-131181

LEI-401 is a first-in-class, selective, and CNS-active **NAPE-PLD** (N-acylphosphatidylethanolamine phospholipase D) inhibitor, with an IC_{50} of 27 nM. LEI-401 modulates emotional behavior in mice.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lp-PLA2-IN-1

Cat. No.: HY-19757

Lp-PLA2-IN-1 is a potent **Lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lp-PLA2-IN-10

Cat. No.: HY-142778

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA2**). Lp-PLA2 previously known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-11

Cat. No.: HY-142779

Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA2**). Lp-PLA2 previously known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-2

Cat. No.: HY-133148

Lp-PLA2-IN-2 is a potent and selective **lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor, with an **IC_{50}** 0f 120 nM for recombinant human Lp-PLA2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-3

Cat. No.: HY-133149

Lp-PLA2-IN-3 is a potent and orally bioavailable **lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor, with an **IC_{50}** of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lp-PLA2-IN-4

Cat. No.: HY-142669

Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA2**). Lp-PLA2 previously known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-5

Cat. No.: HY-142670

Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (**Lp-PLA2**). Lp-PLA2 previously known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-6

Cat. No.: HY-142774

Lp-PLA2-IN-6 (compound 18), a tetracyclic pyrimidinone compound, is a potent **Lp-PLA2** inhibitor with a **pIC_{50}** of 10.0 for rhLp-PLA2. Lp-PLA2-IN-6 has the potential for neurodegenerative related diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lp-PLA2-IN-9

Cat. No.: HY-142777

Lp-PLA2-IN-9 (compound 17), a tetracyclic pyrimidinone compound, is a potent **Lp-PLA2** inhibitor with a **pIC_{50}** of 10.1 for rhLp-PLA2. Lp-PLA2-IN-9 has the potential for neurodegenerative related diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Luffariellolide

Cat. No.: HY-118725

Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (**HSF-PLA2**) (IC_{50}=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED_{50}=50 μg/ear).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 178002

Cat. No.: HY-101579

LY 178002 is a potent inhibitor of **5-lipoxygenase (5-LPO)**, **phospholipase A2**, with **IC_{50}** of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on **cyclooxygenase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY-311727

Cat. No.: HY-107393

LY-311727 is a potent **secretory non-pancreatic phospholipase A_2 ($sPLA_2$)** inhibitor (IC_{50} <1 μM for group IIA $sPLA_2$). $sPLA_2$ is an important proinflammatory enzyme.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

m-3M3FBS

Cat. No.: HY-19619

m-3M3FBS is a potent **phospholipase C (PLC)** activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MAFP
(Methyl Arachidonyl Fluorophosphonate)

Cat. No.: HY-103334

MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of **cPLA2** and **iPLA2**. MAFP is also a potent irreversible inhibitor of **anandamide amidase**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg (27 mM * 500 μL in Methyl acetate)

Manoalide

Cat. No.: HY-N7487

Manoalide is a potent Phospholipase A2 (**PLA2**) and Phospholipase C (**PLC**) inhibitor. Manoalide, a sesterpenoid compound, displays anti-inflammatory and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Manumycin A

Cat. No.: HY-N6796

Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein **farnesyltransferase (FTase)** with respect to farnesylpyrophosphate (K_i =1.2 μM), and as a noncompetitive inhibitor with respect to the **Ras** protein.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Melittin

Cat. No.: HY-P0233

Melittin is a **PLA_2** activator, stimulates the activity of the low molecular weight PLA_2, while it does not the increase activity of the high molecular weight PLA_2.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Melittin TFA

Cat. No.: HY-P0233A

Melittin TFA is a **PLA_2** activator, stimulates the activity of the low molecular weight PLA_2, while it does not the increase activity of the high molecular weight PLA_2.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MJ33 lithium salt

Cat. No.: HY-115062

MJ33 is an active-site-directed, specific, competitive, and reversible **phospholipase A2 (PLA2)** inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MJ33-OH

Cat. No.: HY-129944

MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible **phospholipase A2 (PLA2)** inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MJ33-OH lithium

Cat. No.: HY-129944A

MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible **phospholipase A2 (PLA2)** inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML-211

Cat. No.: HY-128035

ML-211 is a carbamate-based dual inhibitor of **acyl-protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1)** (IC_{50}=17 nM) and **LYPLA2** (IC_{50}=30 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML-298

Cat. No.: HY-116165

ML298 is a potent and selective inhibitor of **Phospholipase D2 (PLD2)** with an IC_{50} of 355 nM. ML298 decreases invasive migration in U87-MG glioblastoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML299

Cat. No.: HY-116273

ML299 is a selective allosteric modulator and a dual inhibitor of **phospholipases D1 and D2** (IC_{50} values are 6 and 12 nM, respectively). ML299 decreases invasive migration in U87-MG glioblastoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML348

(GNF-Pf-1127)

Cat. No.: HY-100736

ML348 (GNF-Pf-1127) is a selective and reversible **acyl-protein thioesterase 1 (APT1)/lysophospholipase 1 (LYPLA1)** inhibitor with an IC_{50} of 210 nM, and barely inhibits LYPLA2.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML349

Cat. No.: HY-100737

ML349 is a potent and specific **acyl protein thioesterase 2(APT2)/lysophospholipase 2 (LYPLA2)** inhibitor with a K_i of 120 nM. ML349 is also an inhibitor of **LYPLA2** with an IC_{50} of 144 nM.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

N-(p-amylcinnamoyl) Anthranilic Acid

(ACA)

Cat. No.: HY-118628

N-(p-amylcinnamoyl) Anthranilic Acid (ACA) is a broad spectrum **Phospholipase A_2 (PLA_2)** inhibitor and **TRP channel** blocker.



Purity: 96.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Neomycin sulfate

Cat. No.: HY-B0470

Neomycin sulfate, an aminoglycoside antibiotic, exerts **antibacterial** activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known **phospholipase C (PLC)** inhibitor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g, 25 g

OBAA

Cat. No.: HY-101015A

OBAA is a potent **phospholipase A2 (PLA2)** inhibitor with an IC_{50} of 70 nM. OBAA blocks Melittin-induced Ca^{2+} influx in Trypanosoma brucei with an IC_{50} of 0.4 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Omeprazole

(H 16868)

Cat. No.: HY-B0113

Omeprazole (H 16868), a **proton pump** inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of **CYP2C19** activity with a K_i of 2 to 6 μM.



Purity: 98.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Omeprazole sodium

(H 16868 sodium)

Cat. No.: HY-B0113A

Omeprazole sodium (H 16868 sodium), a **proton pump** inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of **CYP2C19** activity with a K_i of 2 to 6 μM.



Purity: 98.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Omeprazole-13CD3

(H 16868-13CD3)

Cat. No.: HY-B0113S3

Omeprazole-13CD3 (H 16868-13CD3) is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a **proton pump** inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Omeprazole-d3-1

(H 16868-d3-1)

Cat. No.: HY-B0113S1

Omeprazole-d3-1 (H 16868-d3-1) is the deuterium labeled Omeprazole. Omeprazole (H 16868), a **proton pump** inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

ONO-RS-082

Cat. No.: HY-123070

ONO-RS-082 is an inhibitor of **phospholipase A** (**PLA**). ONO-RS-082 inhibits **PLA2** with the **IC_{50}** of 1.0 μM, but does not inhibit PLC even at 100 μM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PACOCF3

(Palmityltrifluoromethylketone)

Cat. No.: HY-108607

PACOCF3 (Palmityltrifluoromethylketone) is a selective **phospholipase A2** inhibitor with an **IC_{50}** of 3.8 μM. PACOCF3 alters Ca^{2+} signaling in renal tubular cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protizinic acid

Cat. No.: HY-106555

Protizinic acid is an orally active non-steroidal antiinflammatory agent with antiinflammatory and antipyretic activity. Protizinic acid inhibits **phospholipase A2 (PLA2)** activity, and the **IC_{50}** value is 210 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyrrophenone

Cat. No.: HY-111376

Pyrrophenone is a potent and specific cytosolic phospholipase $A_2\alpha$ (**cPLA$_2$α**) inhibitor with an IC_{50} value of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rapanone

Cat. No.: HY-N8213

Rapanone is a natural benzoquinone. Rapanone exhibits a broad spectrum of biological actions, including anti-tumor, antioxidant, anti-inflammatory, antibacterial and antiparasitic.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rhamnetin

Cat. No.: HY-N7036

Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory **phospholipase A2**, with antioxidant and anti-inflammatory activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhamnetin-d3

Cat. No.: HY-N7036S

Rhamnetin-d3 is the deuterium labeled Rhamnetin. Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory **phospholipase A2**, with antioxidant and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RHC 80267

(U-57908)

Cat. No.: HY-107416

RHC 80267 (U-57908) is a potent and selective inhibitor of **diacylglycerol lipase (DAGL)** (with **IC_{50}** of 4 μM in canine platelets). RHC-80267 inhibits **cholinesterase** activity with an **IC_{50}** of 4 μM, thereby enhancing the relaxation evoked by **acetylcholine**.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

ROC-0929

Cat. No.: HY-145384

ROC-0929 (compound 13a) is a potent and selective inhibitor of **secreted phospholipases A_2 (sPLA$_2$s) with an IC_{50} of 80 nM, specially targeting hGX. ROC-0929 inhibits the phosphorylation of ERK1/2 and p-38. Secreted phospholipases A2 (sPLA2s) are a....**



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SPK-601

(LMV-601)

Cat. No.: HY-70083

SPK-601 (LMV-601) is an inhibitor of the **phosphatidylcholine-specific phospholipase C (PC-PLC)**. SPK-601 also can be used as an antimicrobial agent.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

sPLA2 inhibitor 1

Cat. No.: HY-11059

sPLA2 inhibitor 1, a D-tyrosine derivative, is an orally active, potent **secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an **IC_{50}** of 29 nM for human nonpancreatic secretory PLA_2 isoform IIa (hnpsPLA$_2$-IIa). sPLA2 inhibitor 1 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

sPLA2-X Inhibitor 31

Cat. No.: HY-112605

sPLA2-X Inhibitor 31 is a selective **secreted phospholipase A_2 type X** (**$sPLA_2$-X**) inhibitor with **IC<Sub>50**s of 26 nM, 310 nM, and 2230 nM for **$sPLA_2$-X**, **$sPLA_2$-IIa**, and **$sPLA_2$-V**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ST271

Cat. No.: HY-103097

ST271 is a potent inhibitor of protein tyrosine kinase (**PTK**), inhibits **phospholipase D** activation stimulated by fMet-Leu-Phe and PAF, with **IC_{50}**s of 6.7 and 9 μM, respectively.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tanshinone I

(Tanshinone A)

Cat. No.: HY-N0134

Tanshinone I is an inhibitor of type IIA human recombinant **$sPLA_2$** (**IC_{50}**=11 μM) and rabbit recombinant **$cPLA_2$** (**IC_{50}**=82 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

trans-Benzylideneacetone

(trans-Benzalacetone)

Cat. No.: HY-W012595A

trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against **phospholipase A2 (PLA2)**. trans-Benzylideneacetone is an immunosuppressant.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 500 mg

Tris(2,4-di-tert-butylphenyl)phosphate

Cat. No.: HY-136177

Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for **secretory Phospholipase A_2** (**$sPLA_2$**) through molecular docking.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 100 mg

U-73122

Cat. No.: HY-13419

U-73122 is a **phospholipase C (PLC)** and **5-LO (5-lipoxygenase)** inhibitor with an **IC_{50}**of 1-2.1 μM for PLC.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

U-73343

Cat. No.: HY-108630

U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Varespladib

(LY315920)

Cat. No.: HY-13402

Varespladib (LY315920) is a potent and selective **group IIA, secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an **IC_{50}** of 9 nM.



Purity: 98.68%
Clinical Data: Phase 3
Size: 5 mg, 10 mg

Varespladib methyl

(A-002; LY333013)

Cat. No.: HY-17448

Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (**PLA2**).



Purity: 99.45%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Varespladib sodium

(LY315920 sodium) Cat. No.: HY-13402A

Varespladib sodium (LY315920 sodium) is a potent and selective **group IIA, secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an IC_{50} of 9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vinaxanthone

(SM-345431) Cat. No.: HY-N9480

Vinaxanthone (SM-345431) is a potent and selective **semaphorin3A** inhibitor. Vinaxanthone exhibits semaphorin3A inhibiting activity with an IC_{50} of 0.1-0.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0155069

(CAY10593) Cat. No.: HY-108612

VU0155069 (CAY10593), compound 69, is a selective phospholipase D1 (**PLD1**) inhibitor with an IC_{50} value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

VU0359595

(CID-53361951; ML-270) Cat. No.: HY-101293

VU0359595 (CID-53361951; ML-ML-270) is a potent and selective pharmacological phospholipase D1 (**PLD1**) inhibitor with an IC_{50} of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC_{50} of 6.4 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-26734

Cat. No.: HY-108609

YM-26734 is a competitive inhibitor of secretory **phospholipase A^2** (PLA^2) that exhibits a broad inhibitory profile to several PLA2s.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg